Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 203348
Licensee shall provide lead molecules that will be used by Licensor to design and synthesize molecules optimized for activation of the Target.
The Parties shall use commercially reasonable efforts to design and synthesize molecules that are optimized for activation of the Target Molecules based on the lead molecules provided by Licensee.
Licensor shall provide the structure of each such Molecule and any information about the Molecule that is available.
Licensor shall promptly assign to Licensee all such related intellectual property.
Glucokinase is an enzyme that facilitates phosphorylation of glucose to glucose-6-phosphate. Glucokinase occurs in cells in the liver and pancreas of humans and most other vertebrates.
IPSCIO Record ID: 271607
The Licenseeâ€™s research and development efforts with Licensor, a non-profit institute, have been centered on selective screening of certain natural product for the purpose of identifying extracts and further isolating molecules that may be effective as potential anti-inflammatory, neuro-protective and oxidative stress relieving molecules.
IPSCIO Record ID: 291205
Licensor grants a worldwide, exclusive license, with right to sublicense, in the Field under such patent to develop, make, have made, use, sell, offer for sale, have sold, import and have imported Licensed Products, provided that Licensor is not contractually prohibited under a written agreement with a third party from granting such an exclusive license. In the event that Licensor is so contractually prohibited from granting such an exclusive license, Licensor shall grant to Licensee as broad a scope of license as it is permitted (for example, a non-exclusive license) and Licensor shall use its reasonable best efforts to negotiate with such third party to remove such contractual prohibition so as to allow Licensor to grant Licensee the foregoing exclusive license under such Licensor Patents.
For the Unblocking License Grant – Licensor grants a worldwide, nonexclusive license, with right to sublicense, to develop, make, have made, use, sell, offer for sale, have sold, import and have imported Licensor Compounds, Derivative Compounds, and Licensed Products, under any Licensor patent rights which would otherwise be infringed by Licensee but for this license.
DirectedDiversity Technology means Licensor Patents and proprietary know-how that relate to generating and utilizing a DirectedDiversity Chemical Library.
DirectedDiversity(R) Chemi-Informatic Technology uses proprietary computer algorithms to design, select and iteratively refine combinatorial libraries of novel, small-molecule drugs based on screening hits obtained from Licensor or other screening libraries, target-protein 3D structures, or pharmacophore models derived from lead compounds.
Active Compound means a Licensor Compound or Derivative Compound that has been formally selected by Licensee for preclinical and/or clinical development.
Licensee is engaged in research and development of human therapeutic products. The purpose of this collaboration is to identify qualified lead compounds active against selected targets and suitable for medicinal chemistry optimization that may be developed and commercialized by Licensee.
IPSCIO Record ID: 306496
The enzyme Quiescin Sulfhydryl Oxidase 1 (QSOX1) is a master regulator of extracellular matrix remodeling, and its overexpression by tumor cells. Overexpression of QSOX1 has been unambiguously linked to promoting tumor invasion and metastasis. It has been discovered that a small molecule SBI-183 inhibited the enzymatic activity of QSOX1 and as a result suppressed tumor cell invasion in vitro and metastasis of breast tumor cells in vivo.
This license is to technology relating to SBI-183, an anti-metastatic compound suppressing tumor cell growth and blocking metastasis. Small molecule SBI-183 inhibited the enzymatic activity of QSOX1 and as a result suppressed tumor cell invasion in vitro and metastasis of breast tumor cells in vivo. Through its medicinal chemistry efforts the Licensee synthesized multiple structural analogs of SBI-183 and unveiled SPX-1009 lead compound that demonstrated ten-fold improvement in suppressing invasion and metastasis in several cancer models.
SBI-183 enhances the activity of cytotoxic drugs in vitro.
IPSCIO Record ID: 248009
– to research, develop, make and use any or all of the following in connection with the use of the Returned QT to discover or develop Small Molecule Drugs
(1) the Licensor Configured Assay that embodies or is based on a Returned QT, together with the standard operating procedures and reagents necessary, to use such Licensor Configured Assay for such purpose;
(2) if a Second Stage QT is designated as a Returned QT, the most promising lead structure under development by Licensor, and the optimization history of such lead structure and the data pertinent to critical optimization decisions that relate to such lead structure, the Second Stage Information, including without limitation, information on the major structural templates that were evaluated by Licensor and relevant SAR data; and
(3) if a Third Stage QT is designated as a Returned QT, the most promising lead structure under development by Licensor, and the optimization history of such lead structure and the data pertinent to critical optimization decisions that relate to such lead structure, the Third Stage Information, including without limitation, related SAR data, related pharmacological data, including toxicology and ADME information, and information related to chemical synthesis, provided, however, that, in the case of a Second Stage QT or a Third Stage QT, Licensor shall not be obligated to grant any such license with respect to the most promising lead structure if such lead structure is under development by Licensor as a Development Candidate or later stage drug candidate outside of the Licensor Development Program, in which event Licensor shall be obligated to grant such a license with respect to the next most promising lead structure that is not a Development Candidate or later stage drug candidate outside of the Licensor Development Program, and,
– to make, have made, import, use, have used, offer for sale, sell and have sold Small Molecule Drugs that are discovered or developed by Licensee through the use of Returned QTs.
This agreement includes exclusive and non-exclusive grants back to Licensor from Licensee.
Cell-Based Assay means a Licensor Configured Assay that uses a QT incorporated in a cell or presented on the surface of a cell, as distinct from a biochemical assay in which the QT is assayed in a cell-free context.
Qualified Target or QT means a target for Small Molecule drug discovery identified or developed in the course of the Target Discovery Program that has all of the following characteristics
– is a Druggable Target that is a complete coding sequence of a human gene;
– has a Disease/Therapeutic Hypothesis;
– is either a Novel Protein, or fill Unrecognized Protein, or a Druggable Target that is otherwise approved by the Licensor Program Director as a Qualified Target; and
– the use of such target in the manner contemplated in the Research Plan would not, at the time of its identification or annotation in the Target Discovery Program, infringe one or more claims of an issued patent in the country in which such use of the target is expected to occur, unless such target is otherwise approved by the Licensor Program Director.
Non-Exclusive QT means a QT that has a Disease/Therapeutic Hypothesis in both a CFA and Non-CFA and that is designated by Licensee as a Non-Exclusive QT within seven (7) business days after such QT is entered into the QT Pool and a Licensee-Designated NonCFA means one Non-CFA that is associated, on the basis of a Disease/Therapeutic Hypothesis, with a QT, as designated by Licensee at the time such QT is designated a Non-Exclusive QT by Millennium.
IPSCIO Record ID: 367275
With Respect to Analogs, Licensor grants a worldwide, perpetual, non-exclusive license, under Licensor Intellectual Property, to use Analogs and Licensee Analog Information in the discovery of Hits to Licensee Targets, performing Hit-to-Lead Chemistry Programs and Lead Optimization Programs and in the Development of Royalty-Bearing Products and Non-Royalty-Bearing Products that contain Analogs, which license shall include the right to use Synthetic Methodology and Pathways solely to synthesize Analogs.
Target shall mean a protein or polypeptide, which is involved in a biological process as well as orthologs thereof and all isoforms or polymorphisms, including single nucleotide polymorphisms, alleles, and other naturally-occurring or synthetic derivatives, including, without limitation, insertions, additions, deletions, fragments and splice variants thereof and nucleic acid sequences encoding any of the above that is configured into one or more assays for screening, including, but not limited to, in vitro assays and phenotypic or pathway screens, cell-based or in vivo assays, or used for structure-based compound design.
Library Compound shall mean a compound that Licensor delivered pursuant to the Prior Agreement.
Library Compound Information shall mean structural, process or other information relating to a Library Compound.
Library Compound Structure Information shall mean documentation of the molecular formula and molecular structure of each Library Compound.
Hit shall mean a Library Compound or an Analog that is confirmed as active against a Licensee Target, or for which computational data is generated which predicts activity, which is subsequently confirmed as active against a Licensee Target.
A Licensee Analog is designed, discovered or synthesized by Licensee in the course of a Drug Discovery Program.
Synthetic Methodology and Pathways shall mean, with respect to a Library Compound, the synthetic scheme that Licensor used to synthesize the Library Compound,
IPSCIO Record ID: 230755
Prototype Compound means a compound discovered using information obtained from a Hit in the course of Prototype Compound Generation having a dissociation constant less than or equal to 0.5 ÂµM as determined in a dose response experiment and which demonstrates a desired activity against a Target in a molecular or cellular functional assay. Prototype Compounds will have pharmaceutically acceptable properties as determined by the Licensee prior to initiation of Prototype Compound Generation and confirmed in a series of in vitro assays, including p450 metabolism, p450 inhibition, logP, logD, pKa, Caco-2 permeability and solubility. Prototype Compounds will be identified as Prototype Compounds by the Licensee within thirty (30) days of delivery of data from such in vitro assays. For purposes of clarity, the Licensee may, at its discretion, select a compound as a Prototype Compound even if such compound does not meet the criteria set forth above.
Prototype Compound Generation means a program for discovering Prototype Compounds using information obtained from Hits, and iterative rounds of chemistry and the Licensor Synthetically Accessible Library to make Focused Libraries for rescreening using ThermoFluor(R) Technology against such Target.
Licensor Synthetically Accessible Library means Licensors virtual compound library as it exists from time to time from which Licensor Probe Libraries have been selected, and from which Focused Libraries will be selected.
Licensor Probe Library means the sample compound library or any subset thereof, comprised of proprietary and non-proprietary compounds which are owned or Controlled by Licensor or to the extent not encumbered by a bona fide third party interest, that have been synthesized for the purposes of fulfilling Licensors obligations under this Agreement, which is used for the screening of Targets using ThermoFluor(R) Technology for the purpose of identification of Hits, Prototype Compounds, or Active Compounds. While the individual non-proprietary compounds in the Licensor Probe Library are not proprietary, the collection itself, and the list, as a whole, of non-proprietary compounds included in the collection, are the 'Confidential Information' of Licensor.
Active Compound means a compound(s) claimed by a Valid Claim of a Licensor Patent, Joint Patent or Research Program Patent Right.
ThermoFluor(R) Technology means the technology described in
(a) the Licensor Patents identified below, and (b) associated proprietary Licensor Know-how used to evaluate ligand binding parameters of Hits, Prototype Compounds, and Active Compounds.
6,020,141 – Microplate Thermal Shift Assay for Ligand Development and Multi-variable Protein Chemistry Optimization
6,036,920 – Microplate Thermal Shift Assay for Ligand Development and Multi-variable Protein Chemistry Optimization
6,291,191 – Microplate Thermal Shift Assay for Ligand Development and Multi-variable Protein Chemistry Optimization
DirectedDiversity(R)Technology means the technology described in
(a) the Licensor Patents identified below, and (b) associated proprietary Licensor know-how used to identify Hits, Prototype Compounds, and Active Compounds.
5,463,564 – System and Method of Automatically Generating Chemical Compounds with Desired Properties
5,574,656 – System and Method of Automatically Generating Chemical Compounds with Desired Properties
5,684,711 – System and Method of Automatically Generating Chemical Compounds with Desired Properties
IPSCIO Record ID: 223145
This DiscoverWorksâ„¢ agreement is a research and development collaboration to identify Initial Hits, Improved Hits, Program Lead Compounds and Pre-Clinical Lead Compounds active against selected targets, and suitable, if required, for medicinal chemistry optimization, that may be developed and commercialized.
Licensed Product means any commercial product containing an Active Compound as an active ingredient.
Active Compound means a Program Lead Compound or a Pre-Clinical Lead Compound identified in the course of the Research Program, or compound further optimized from such a Program Lead Compound or a Pre-Clinical Lead Compound.
Chemical Optimization means the design, synthesis and identification of Improved Hits, Program Lead Compounds and Pre-Clinical Lead Compounds using DiscoverWorksâ„¢ Technology and other technologies.
DiscoverWorksâ„¢ Technology means DirectedDiversityÂ® Technology and ThermoFluorÂ® Technology.
DirectedDiversity(R) Technology means the descriptions, figures and claims of the Patent Rights and associated proprietary Licensor Know-how used to identify potential therapeutic compounds.
ThermoFluorÂ® Technology means the Patent Rights and associated proprietary Licensor Know-how used to evaluate ligand-binding parameters.
IPSCIO Record ID: 203296
Licensor is a biopharmaceutical company which is focused on the discovery, development and commercialization of small molecules which target post-transcriptional control of protein expression, and which owns certain proprietary technologies for developing small molecule drugs by targeting such post transcriptional control mechanisms, including GEMS.
GEMS (Gene Expression Modulation by Small-Molecules) is a novel drug discovery platform technology which enables identification of compounds that target the post-transcriptional regulation of gene expression.
Gene Expression Modulation by Small-molecules (GEMS) is PTCâ€™s novel and proprietary screening technology for the identification of small-molecules that modulate post-transcriptional control mechanisms. Compounds identified through the GEMS technology modulate gene expression by targeting the post-transcriptional control processes that act through the untranslated regions (UTRs) of messenger RNA (mRNA) molecules.
Parties wish to collaborate on specific therapeutic targets with a focus on cardiovascular, metabolic and addictive diseases, and the discovery of clinical candidate small molecules which act upon such targets.
This agreement pertains to drug discovery.